Oral sodium bicarbonate to reduce contrast induced nephropathy

Phase 4

Recruiting

• Conditions: Coronary artery disease; Renal impairment; Renal and Urogenital - Kidney disease; Diabetes mellitus; Contrast induced nephropathy; Cardiovascular - Coronary heart disease

• Registration Number: ACTRN12608000205336
• Lead Sponsor: Michael Mok

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2008-04-16
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Estimated glomerular filtration rate < 60mL/min
Adults > 18years old
Able to provide informed consent
Awaiting elective coronary angiography

Exclusion Criteria

New York Heart Association III or IV
Acute myocardial infarction
Acute pulmonary oedema
Pregnancy
Renal replacement therapy
Medical kidney disease (multiple myeloma, acute nephritis)
Prior use of N-acetylcysteine or sodium bicarbonate or intravenous contrast agent in the preceding 4 weeks

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Incidence of contrast induced nephropathy in active and placebo groups[Day 2 and Day 7 renal function assessment from time of angiography]

Secondary Outcome Measures

Name	Time	Method
Assess the rate of contrast induced nephropathy in patients with diabetes mellitus and pre-morbid renal impairment.[Day 2 and Day 7 renal function assessment from time of angiography.]